Relmada Therapeutics, Inc. RLMD
Set alert
4.10 USD +0.25 +6.64%
As of Nov 3, 10:54 AM ET
3.88 Day range 4.23
2.19 52-week range 8.00
- YTD
- -15.22%
- 1 year
- +86.14%
- Open
- 3.88
- Prev close
- 3.84
- Mkt cap
- 436.28M
- Vol
- 598.50K
- Avg vol
- 1.34M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.88
- High
- 4.23
- Forward P/E
- -0.19
- Beta
- 0.41
- Short ratio
- 4.52
- Inst. own
- 46.06%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.53
- 200-d avg
- 3.33
- 1y target
- 0.86667
1M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
Analyst view
Consensus: none
Price target (mean) 0.86667 -78.8% downside
Now 4.10
- Target (low)
- 0.60
- Target (mean)
- 0.86667
- Target (high)
- 1.00
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 4
- 2 months ago 4
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -1.72 | -1.72 – -1.72 | -3.27 | +47.5% | 0 | 0.0% | 1 |
| Next year | -1.31 | -1.31 – -1.31 | -1.72 | +23.8% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Mizuho | Downgrade | Outperform | Neutral |
| Dec 4, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Jun 5, 2024 | Goldman Sachs | Downgrade | Neutral | Sell |
| Jun 15, 2023 | Mizuho | Reiterated | Buy | Buy |
| Jan 23, 2023 | SVB Leerink | Maintained | — | Outperform |
| Oct 14, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Oct 14, 2022 | Guggenheim | Downgrade | Buy | Neutral |
| Oct 13, 2022 | Oppenheimer | Downgrade | Outperform | Perform |
| Sep 23, 2022 | Goldman Sachs | Maintained | — | Buy |
| Sep 6, 2022 | Guggenheim | Maintained | — | Buy |
| May 9, 2022 | Oppenheimer | Maintained | — | Outperform |
| Mar 24, 2022 | Goldman Sachs | Maintained | — | Buy |
| Dec 20, 2021 | SVB Leerink | Maintained | — | Outperform |
| Nov 18, 2021 | Mizuho | Initiated | — | Buy |
| Oct 28, 2020 | Goldman Sachs | Downgrade | Buy | Neutral |
| May 4, 2020 | SunTrust Robinson Humphrey | Initiated | — | Buy |
| Apr 21, 2020 | Goldman Sachs | Initiated | — | Buy |
| Jan 27, 2020 | Jefferies | Initiated | — | Buy |
| Dec 16, 2019 | Guggenheim | Initiated | — | Buy |